NCT01614093

Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: University of Maryland, Baltimore · Academic / Other
• Sex: All
• Age: 18 Years – 54 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to test a single dose of intranasal oxytocin, compared to placebo, in a within subjects, crossover design, to see if oxytocin will improve satiety signaling (behaviorally and/or by self report) compared to placebo. If this single dose pilot paradigm shows an increase in satiety, it may be tested in follow-up studies as a prevention or treatment for weight gain and overeating in people with schizophrenia.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Oxytocin	Single dose intranasal oxytocin (24 IU)
DRUG	Placebo	Placebo- Sugar pill

Timeline

• Start date: 2012-06-01
• Primary completion: 2014-01-01
• Completion: 2014-01-01
• First posted: 2012-06-07
• Last updated: 2019-08-28
• Results posted: 2017-09-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study